Citigroup Inc Clovis Oncology, Inc. Transaction History

Citigroup Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	SELL	$1.05 - $2.85 $37,761 - $102,494	-35,963 Reduced 95.35%	1,752 $2,000
Q2 2022 Aug 10, 2022	SELL	$0.63 - $2.96 $63,758 - $299,563	-101,204 Reduced 72.85%	37,715 $68,000
Q1 2022 May 12, 2022	SELL	$1.43 - $3.14 $1.26 Million - $2.77 Million	-881,432 Reduced 86.39%	138,919 $281,000
Q4 2021 Feb 10, 2022	BUY	$2.7 - $4.76 $1.5 Million - $2.65 Million	557,021 Added 120.22%	1,020,351 $2.77 Million
Q3 2021 Nov 10, 2021	BUY	$4.06 - $5.8 $1.88 Million - $2.69 Million	463,330 New	463,330 $2.07 Million

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.